Tag: chronic kidney disease
-
Finerenone and the CKM “third pillar” — complementarity is a division of outcomes, and the anti-fibrotic expansion is preclinical-thick but human-empty
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, not medical advice. The 30-second version What. Finerenone completes the cardio-kidney-metabolic (CKM) “three-pillar” standard of care alongside SGLT2 inhibitors and GLP-1 agonists through a non-overlapping anti-inflammatory / anti-fibrotic axis. But the real substance…
-
Does finerenone move hard outcomes, or mainly organ and morbidity endpoints? A close read of FIDELITY, FINEARTS-HF and FINE-HEART
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, and not medical advice. The 30-second version What. Finerenone (a non-steroidal mineralocorticoid receptor antagonist) reduced kidney and heart-failure morbidity endpoints consistently across three pooled trial layers. But the single hardest endpoint, cardiovascular death,…
-
The finerenone landscape — a nonsteroidal MRA as the third pillar of CKM care, and what is still an open question
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, not medical advice. The 30-second version What. Finerenone is a nonsteroidal mineralocorticoid receptor antagonist (MRA) that targets inflammation and fibrosis rather than blood pressure and volume — a mechanism that does not overlap…
-
Do incretins move hard outcomes in CKM, not just weight? A close read of SELECT, FLOW and SUMMIT
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, and not medical advice. The 30-second version What. GLP-1 / incretin agents lowered hard cardiovascular (SELECT) and kidney (FLOW) outcomes. In SELECT’s pre-specified analysis, roughly two-thirds of the cardiovascular benefit appeared independent of…
-
Who names the disease — America’s CKM and Europe’s SMD, two axes of definitional power over metabolic disease
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, and not medical advice. The 30-second version What. Two upper-level disease taxonomies are competing over the cardio-renal-metabolic continuum. In the United States, the AHA-led CKM (Cardiovascular-Kidney-Metabolic) Syndrome (2023 advisory → 2026 multisociety guideline).…
Uthando Nethemba 